AR049021A1 - Tratamiento de trastornos con un anticuerpo que se une a cd20 - Google Patents
Tratamiento de trastornos con un anticuerpo que se une a cd20Info
- Publication number
- AR049021A1 AR049021A1 ARP050101492A ARP050101492A AR049021A1 AR 049021 A1 AR049021 A1 AR 049021A1 AR P050101492 A ARP050101492 A AR P050101492A AR P050101492 A ARP050101492 A AR P050101492A AR 049021 A1 AR049021 A1 AR 049021A1
- Authority
- AR
- Argentina
- Prior art keywords
- effective amount
- mammal
- agent
- administering
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Tratamiento de la policondritis o mononeuritis multiple en un mamífero con una cantidad eficaz de un anticuerpo que se une a CD20, opcionalmente también con otro agente que trata ese tipo de trastornos en una cantidad eficaz. Reivindicacion 4: El método de acuerdo con la reivindicacion 3 en el cual la otra molécula es un agente citotoxico. Reivindicacion 5: El método de acuerdo con la reivindicacion 4 en el cual el agente citotoxico es un compuesto radioactivo. Reivindicacion 15: El método de acuerdo con cualquiera de las reivindicaciones 1-14 que comprende además administrar al mamífero una cantidad eficaz de un agente inmunosupresivo, agente contra el dolor o un agente quimioterapéutico. Reivindicacion 17: El método de acuerdo con la reivindicacion 16 que comprende además administrar al mamífero una cantidad eficaz de un fármaco antiinflamatorio no esteroide, esteroide, metotrexato, ciclofosfamida, dapsona, azatioprina, penicilamina, o ciclosporina. Reivindicacion 19: El método de acuerdo con la reivindicacion 18 que comprende además administrar al mamífero una cantidad eficaz de un agente contra el dolor, esteroide, metotrexato, ciclofosfamida, intercambio plasmático, inmunoglobulina intravenosa, ciclosporina, o miconfenolato mofetilo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56322704P | 2004-04-16 | 2004-04-16 | |
US56509804P | 2004-04-22 | 2004-04-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR049021A1 true AR049021A1 (es) | 2006-06-21 |
Family
ID=35207581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050101492A AR049021A1 (es) | 2004-04-16 | 2005-04-15 | Tratamiento de trastornos con un anticuerpo que se une a cd20 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20060002930A1 (es) |
EP (1) | EP1742660A2 (es) |
JP (1) | JP2007532680A (es) |
AR (1) | AR049021A1 (es) |
AU (1) | AU2005247303A1 (es) |
BR (1) | BRPI0509412A (es) |
CA (1) | CA2562243A1 (es) |
IL (1) | IL178553A0 (es) |
NO (1) | NO20065252L (es) |
RU (1) | RU2006140374A (es) |
TW (1) | TW200603828A (es) |
WO (1) | WO2005115453A2 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000067796A1 (en) * | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
CA2422076A1 (en) * | 2000-09-18 | 2002-03-21 | Idec Pharmaceutical Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
EA036531B1 (ru) | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение |
CA2577133A1 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
AU2006320162B2 (en) * | 2005-12-02 | 2013-07-25 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
AU2006329944A1 (en) * | 2005-12-09 | 2007-07-05 | Seattle Genetics, Inc. | Methods of using CD40 binding agents |
US7846724B2 (en) † | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
WO2008034071A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Method of identifying patients suitable for high-dose cyclophosphamide treatment |
WO2008034076A2 (en) * | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
RS53850B2 (sr) * | 2007-10-30 | 2018-07-31 | Genentech Inc | Pročišćavanje antitela hromatografijom izmene katjona |
US9026372B2 (en) * | 2007-11-21 | 2015-05-05 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen |
WO2009067690A2 (en) * | 2007-11-21 | 2009-05-28 | Accentia Biopharmaceuticals, Inc. | Methods for safe and effective treatment using oxazaphosphorine drugs |
TW201014605A (en) * | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
US8815242B2 (en) * | 2009-05-27 | 2014-08-26 | Synageva Biopharma Corp. | Avian derived antibodies |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
KR101436219B1 (ko) | 2009-10-26 | 2014-09-01 | 에프. 호프만-라 로슈 아게 | 글리코실화된 면역글로불린의 제조 방법 |
AU2011203879A1 (en) * | 2010-01-11 | 2012-08-02 | Alexion Pharmaceuticals, Inc. | Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies |
CN102933231B (zh) | 2010-02-10 | 2015-07-29 | 伊缪诺金公司 | Cd20抗体及其用途 |
US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US128468A (en) * | 1872-07-02 | Improvement in transferring the natural grain of wood | ||
US82172A (en) * | 1868-09-15 | Frank stanley | ||
US9444A (en) * | 1852-12-07 | Hot-air furnace | ||
US197255A (en) * | 1877-11-20 | Improvement in receivers and stench-traps for street-sewers | ||
US25764A (en) * | 1859-10-11 | Improvement in cultivators | ||
US69545A (en) * | 1867-10-08 | curtis | ||
US58029A (en) * | 1866-09-11 | Improved window-shade fastening | ||
US133930A (en) * | 1872-12-17 | Improvement in toy spring-guns | ||
US219433A (en) * | 1879-09-09 | Improvement in grain-binders | ||
US219818A (en) * | 1879-09-23 | Improvement in evaporating-pans | ||
US6404A (en) * | 1849-05-01 | shaw and ezra gould | ||
US12665A (en) * | 1855-04-10 | Improvement sssi steam-boilers | ||
US185796A (en) * | 1876-12-26 | Improvement in chairs | ||
US136719A (en) * | 1873-03-11 | Improvement in travelers for spinning-rings | ||
US180292A (en) * | 1876-07-25 | Improvement in folding chairs | ||
US41847A (en) * | 1864-03-08 | Improved washing-machine | ||
US18041A (en) * | 1857-08-25 | Xwashing-machine | ||
US147885A (en) * | 1874-02-24 | Improvement in the manufacture of halters and bridles | ||
US103971A (en) * | 1870-06-07 | Improvement in mechanical movement | ||
US93621A (en) * | 1869-08-10 | Improvement in wagon s | ||
US26801A (en) * | 1860-01-10 | peters | ||
US9427A (en) * | 1852-11-23 | Whifeletree | ||
US4587A (en) * | 1846-06-20 | Machine for lasting shoes and boots | ||
US157108A (en) * | 1874-11-24 | Improvement in lubricating compounds | ||
US197256A (en) * | 1877-11-20 | Improvement in saw-handles | ||
US21781A (en) * | 1858-10-12 | Improved method o f lighting street-lamps by electricity | ||
US88664A (en) * | 1869-04-06 | Improved device tor mowing- away hat | ||
US965963A (en) * | 1910-03-10 | 1910-08-02 | Harry E Blanchard | Burner for fuel-oils. |
US1156066A (en) * | 1915-06-18 | 1915-10-12 | John W Dupuy | Stove. |
IL47062A (en) * | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
US4665077A (en) * | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
US4485045A (en) * | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) * | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5576195A (en) * | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5567610A (en) * | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US6893625B1 (en) * | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5283187A (en) * | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US4892538A (en) * | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5506126A (en) * | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
IL85746A (en) * | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
US4861579A (en) * | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5229275A (en) * | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5571894A (en) * | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
ES2206447T3 (es) * | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5587458A (en) * | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
ATE244763T1 (de) * | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
US5573905A (en) * | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
CA2149329C (en) * | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
JP3194680B2 (ja) * | 1994-12-15 | 2001-07-30 | 三菱電機株式会社 | 内燃機関の失火検出装置 |
US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) * | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6368596B1 (en) * | 1997-07-08 | 2002-04-09 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) * | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
EP1112084B2 (en) * | 1998-08-11 | 2012-04-25 | Biogen Idec Inc. | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
US6224866B1 (en) * | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
DE19930748C2 (de) * | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
NZ592087A (en) * | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
CA2476166C (en) * | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
US20050180972A1 (en) * | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
US20040032828A1 (en) * | 2002-08-16 | 2004-02-19 | Cellglide Technologies Corp. | Service management in cellular networks |
SI1558648T1 (sl) * | 2002-10-17 | 2012-05-31 | Genmab As | Človeška monoklonalna protitelesa proti CD |
ES2322267T3 (es) * | 2003-04-09 | 2009-06-18 | Genentech, Inc. | Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa. |
-
2005
- 2005-04-15 RU RU2006140374/14A patent/RU2006140374A/ru not_active Application Discontinuation
- 2005-04-15 BR BRPI0509412-7A patent/BRPI0509412A/pt not_active IP Right Cessation
- 2005-04-15 US US11/106,820 patent/US20060002930A1/en not_active Abandoned
- 2005-04-15 JP JP2007508593A patent/JP2007532680A/ja not_active Withdrawn
- 2005-04-15 AU AU2005247303A patent/AU2005247303A1/en not_active Abandoned
- 2005-04-15 EP EP05780026A patent/EP1742660A2/en not_active Withdrawn
- 2005-04-15 WO PCT/US2005/012961 patent/WO2005115453A2/en active Application Filing
- 2005-04-15 AR ARP050101492A patent/AR049021A1/es not_active Application Discontinuation
- 2005-04-15 CA CA002562243A patent/CA2562243A1/en not_active Abandoned
- 2005-04-18 TW TW094112278A patent/TW200603828A/zh unknown
-
2006
- 2006-09-26 US US11/535,459 patent/US20070031331A1/en not_active Abandoned
- 2006-10-15 IL IL178553A patent/IL178553A0/en unknown
- 2006-11-15 NO NO20065252A patent/NO20065252L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1742660A2 (en) | 2007-01-17 |
US20060002930A1 (en) | 2006-01-05 |
AU2005247303A1 (en) | 2005-12-08 |
RU2006140374A (ru) | 2008-05-27 |
US20070031331A1 (en) | 2007-02-08 |
TW200603828A (en) | 2006-02-01 |
BRPI0509412A (pt) | 2007-09-04 |
JP2007532680A (ja) | 2007-11-15 |
IL178553A0 (en) | 2007-02-11 |
NO20065252L (no) | 2007-01-15 |
CA2562243A1 (en) | 2005-12-08 |
WO2005115453A2 (en) | 2005-12-08 |
WO2005115453A3 (en) | 2006-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR049021A1 (es) | Tratamiento de trastornos con un anticuerpo que se une a cd20 | |
RU2428982C2 (ru) | Применение соединения | |
AR049358A1 (es) | Una composicion farmaceutica de un acido graso poliinsaturado o su sal o derivado con al menos un inmunosupresor o un agente anti neoplasico y su uso | |
BR0308451A (pt) | Composto, composição farmacêutica, métodos para o tratamento, prevenção ou melhoria de disfunção e método de fabricação de composto | |
EA200400737A1 (ru) | Препарат аминокислот и рибофлавина, применимый для уменьшения токсического действия цитотоксической химиотерапии | |
PT99887A (pt) | Processo para a preparacao de anticorpos monoclonais contra o factor alfa de necrose tumoral humano | |
KR910000169A (ko) | 포유류에서 이식 거부를 억제시키는 라파마이신의 용도 | |
HUP0201314A2 (hu) | Aril-szubsztituált pirazolok, imidazolok, oxazolok, tiazolok és pirrolok, valamint ezek alkalmazása és az ezeket tartalmazó gyógyászati készítmények | |
PE20060002A1 (es) | Combinaciones antineoplasicas de cci-779 y rituximab | |
UY28287A1 (es) | Combinaciones para el tratamiento de enfermedades que impican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis | |
PE20060879A1 (es) | Formulacion anticuerpo anti a beta | |
ATE525398T1 (de) | Epha2 monoklonale antikörper und deren anwendungsverfahren | |
MA31890B1 (fr) | Anticorps specifiques de la forme de protofibrille de proteine beta - amyloide | |
MA29273B1 (fr) | Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur | |
AR069979A1 (es) | Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados | |
BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
AR060089A1 (es) | Tratamiento del dolor | |
WO2005074536A3 (en) | Compositions and methods using proton pump inhibitors | |
CO5011041A1 (es) | Composicion farmaceutica | |
Ludwig et al. | Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial | |
MA56827B2 (fr) | Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine | |
AR032989A1 (es) | Una composicion farmaceutica util para el tratamiento del cancer | |
BR0111868A (pt) | Composições farmacêuticas | |
Busca et al. | Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation | |
Mak et al. | Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |